In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.

This was the stock's second consecutive day of gains.

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...

For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an ...

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Although sometimes overshadowed by the all-important income statement, the balance sheet can offer essential insights into a ...